GlassScriptPhysician profile
Katherine C Gilbert
NPI 1871814467
$4,994.32
in general payments reported to CMS, 2019-2025
25 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,839 · 2024: $1,339 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,366 · Consulting Fee: $1,620 · Education: $8.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,366.46 |
| Consulting Fee | $1,619.61 |
| Education | $8.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,600.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $1,028.35 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $591.23 | 2023-2025 | |
| Glaxosmithkline, LLC. | $296.26 | 2023-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $244.86 | 2023-2025 | Dupixent |
| Amgen INC. | $153.57 | 2024-2025 | Tezspire |
| Grifols USA, LLC | $150.70 | 2024-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $119.98 | 2023-2025 | Eohilia, Takhzyro, Cuvitru |
| Genentech USA, INC. | $98.50 | 2024-2025 | Xolair |
| Biocryst US Sales Co., LLC | $91.84 | 2024-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $84.57 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $83.80 | 2025 | Neffy |
| Kaleo, INC. | $72.98 | 2024 | Auvi-Q |
| Blueprint Medicines Corporation | $69.59 | 2024 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $66.72 | 2025 | Dawnzera |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $58.20 | 2024-2025 | |
| Octapharma USA, INC. | $30.17 | 2024 | Cutaquig |
| Pfizer INC. | $29.16 | 2025 | |
| Alk-Abello, INC | $24.72 | 2025 | Odactra, Grastek |
| Pharming Healthcare, INC. | $24.31 | 2025 | Ruconest |
| Kedrion Biopharma, INC. | $21.01 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Organon LLC | $20.04 | 2025 | |
| Adma Biomanufacturing LLC | $19.61 | 2025 | |
| Cycle Pharmaceuticals INC | $14.15 | 2025 | Sajazir |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,564.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.